FDA
-
-
-
-
-
-
-
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
-
-
-
-
-
-
-
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
-
-
-
-
-
-
-
MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions
-
-
-
-
-
-
-
MEI Pharma (MEIP) Responds to Anson and Cable Car
-
-
-
-
-
-
-
ISS Recommends Infinity Pharmaceuticals (INFI) Stockholders Vote FOR the Merger with MEI Pharma, Inc. (MEIP)
-
-
-
-
-
-
-
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
-
-
-
-
-
-
-
MEI Pharma (MEIP) confirms $8/share unsolicited and non-binding takeover proposal from Anson Advisors
-
251,413 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All